Literature DB >> 1533441

Nuclear factor of activated T cells contains Fos and Jun.

J Jain1, P G McCaffrey, V E Valge-Archer, A Rao.   

Abstract

The nuclear factor NF-AT (ref. 1) is induced in T cells stimulated through the T-cell receptor/CD3 complex, and is required for interleukin-2 (IL-2) gene induction. Although NF-AT has not been cloned or purified, there is evidence that it is a major target for immunosuppression by cyclosporin A (CsA) and FK506 (refs 2-7). NF-AT induction may require two activation-dependent events: the CsA-sensitive translocation of a pre-existing component and the CsA-resistant synthesis of a nuclear component. Here we report that the newly synthesized nuclear component of NF-AT is the transcription factor AP-1. We show that the inducible nuclear form of NF-AT contains Fos and Jun proteins. Furthermore, we identify a pre-existing NF-AT-binding factor that is present in hypotonic extracts of unstimulated T cells. On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533441     DOI: 10.1038/356801a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  127 in total

1.  NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun.

Authors:  C Lopez-Rodríguez; J Aramburu; A S Rakeman; A Rao
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses.

Authors:  Takeshi Fujii; Yoshihiro Watanabe; Tomoyuki Inoue; Koichiro Kawashima
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  Structure of the sporulation-specific transcription factor Ndt80 bound to DNA.

Authors:  Jason S Lamoureux; David Stuart; Roger Tsang; Cynthia Wu; J N Mark Glover
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

Review 5.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

6.  Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation.

Authors:  Shih-Chu Kao; Hai Wu; Jianming Xie; Ching-Pin Chang; Jeffrey A Ranish; Isabella A Graef; Gerald R Crabtree
Journal:  Science       Date:  2009-01-30       Impact factor: 47.728

7.  Involvement of hydrogen peroxide in asbestos-induced NFAT activation.

Authors:  Jingxia Li; Bihui Huang; Xianglin Shi; Vincent Castranova; Val Vallyathan; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Differential roles for Fos and Jun in DNA-binding: redox-dependent and independent functions.

Authors:  L Ng; D Forrest; T Curran
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

9.  Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells.

Authors:  K T Shaw; A M Ho; A Raghavan; J Kim; J Jain; J Park; S Sharma; A Rao; P G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Calcineurin potentiates activation of the granulocyte-macrophage colony-stimulating factor gene in T cells: involvement of the conserved lymphokine element 0.

Authors:  A Tsuboi; E S Masuda; Y Naito; H Tokumitsu; K Arai; N Arai
Journal:  Mol Biol Cell       Date:  1994-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.